ST Elevation Myocardial Infarction Clinical Trial
— FIRSTOfficial title:
Field Implementation of the autoRIC Device in STEMI
NCT number | NCT03265067 |
Other study ID # | 16-0008 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | July 4, 2016 |
Est. completion date | July 26, 2019 |
Verified date | October 2019 |
Source | William Osler Health System |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a "before and after" observational study of a therapeutic strategy to treat patients
with confirmed ST-segment myocardial infarction (STEMI) with remote ischemic conditioning
(RIC) before undergoing primary percutaneous coronary intervention (PCI). RIC is the
purposeful application of brief, intermittent cycles of limb occlusion by inflation/deflation
of a pneumatic cuff. The autoRIC device is an automatic RIC delivery device (the autoRIC®
Device; CellAegis Devices Inc, Toronto, ON) that has received clearance from Health Canada
for this use under the direction of a health care professional. Paramedics in the Peel and
Halton regional emergency services and the Emergency department (ED) staff of Brampton Civic
Hospital and Mississauga Hospital will treat patients experiencing STEMI with autoRIC, and
study data will be collected from existing patient records.
The 'before' group will include up to 900 patients who were treated before autoRIC
implementation in the services and hospitals. These patients would have had a STEMI and
undergone PCI, but did not receive the autoRIC device. The 'after' group will include up to
900 eligible patients who have had RIC treatment with the autoRIC device at the two
participating sites following implementation in the services and hospitals.
The primary analyses will compare the short-term and long-term outcomes of eligible patients
who have received completed primary PCI for STEMI in the time period before the
implementation and following the implementation of this RIC strategy. In addition, a health
economic analysis will be conducted to determine the cost-effectiveness of the therapeutic
strategy to treat STEMI patients with RIC prior to PCI.
Status | Completed |
Enrollment | 1622 |
Est. completion date | July 26, 2019 |
Est. primary completion date | July 26, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - 18 years of age and older; - patients diagnosed with STEMI in the prehospital environment by responding paramedics from Peel Regional Paramedic Services or Halton Emergency Medical Service and transported to the PCI laboratory of Brampton Civic Hospital or Trillium Health Partners; - walk-in patients diagnosed with STEMI in the ED of either of these two facilities. Exclusion Criteria: - left-bundle branch block; - Lymphedema on either arm - PICC Line on either arm - AV fistula or no palpable pulse on either arm; - patient has a known bleeding disorder or known abnormality of blood flow to the left arm; - patient has peripheral nerve injury, abnormal nerve supply, peripheral neuropathy or pre- existing traumatic injury to the limb to be treated (left-arm). |
Country | Name | City | State |
---|---|---|---|
Canada | Brampton Civic Hospital | Brampton | Ontario |
Canada | The Mississauga Hospital | Mississauga | Ontario |
Lead Sponsor | Collaborator |
---|---|
William Osler Health System | CellAegis US, Inc., Halton Region Paramedic Services, Peel Regional Paramedic Service, Sunnybrook Health Sciences Centre, Trillium Health Centre |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 90-day MACCE | Major adverse cardiovascular and cerebrovascular events (MACCE) in-hospital and within 90 days of PCI. | Within 90 days of PCI | |
Secondary | 30, 60 and 180-day MACCE | MACCE within 30, 60 and 180 days post hospital admission | Within 30, 60 and 180 days of admission | |
Secondary | LOS | Index hospitalization length of stay (LOS) | Time from hospital admission to hospital discharge, up to 180 days of admission | |
Secondary | Cardiovascular-related death | Death due to cardiovascular related events | Time from hospital admission to hospital discharge, up to 180 days of admission | |
Secondary | 30, 60, and 180-day cardiovascular-related readmission | Hospital readmission within 30, 60, and 180 days of index hospitalization, due to cardiovascular events. | 30, 60 and 180 days after index hospitalization | |
Secondary | Infarct size | Size of infarct as measured by peak troponin level during index event admission | Time from hospital admission to hospital discharge, up to 180 days of admission |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05601999 -
Study of Efficacy and Safety of GNR-060 vs Metalyse in Patients With ST Elevation Myocardial Infarction
|
Phase 3 | |
Recruiting |
NCT06147986 -
Evaluate the Efficacy and Safety of Allogeneic Umbilical Cord Mesenchymal Stem Cells as an Add-On Treatment for Acute ST-elevation Myocardial Infarction (STEMI) Patients
|
Phase 2 | |
Not yet recruiting |
NCT05881382 -
Dutogliptin in Co-administration With Filgrastim in Early Recovery Post-myocardial Infarction
|
Phase 3 | |
Enrolling by invitation |
NCT02615015 -
SNPs in the DNase 1 Gene Impair Its Activity and Are Increased in a STE-ACS Patient Cohort Compared to Healthy Controls
|
N/A | |
Recruiting |
NCT05812963 -
IVUS Versus FFR for Non-infarct Related Artery Lesions in Patients With Multivessel Disease and Acute STEMI
|
N/A | |
Recruiting |
NCT05554588 -
Intrathrombus Thrombolysis Versus Aspiration Thrombectomy During Primary PCI
|
N/A | |
Recruiting |
NCT05450757 -
Shanghai ST-segment Elevation Myocardial Infarction Cohort
|
||
Active, not recruiting |
NCT03278509 -
Evaluation of Decreased Usage of Betablockers After Myocardial Infarction in the SWEDEHEART Registry (REDUCE-SWEDEHEART)
|
Phase 4 | |
Not yet recruiting |
NCT03263468 -
Revascularization StrategIes for ST Elevation Myocardial Infarction Trial
|
N/A | |
Completed |
NCT03156699 -
The Incidence, Effect and Persistence of Fragmented-QRS, in Patients Presenting With ST-Elevation Myocardial Infarction
|
||
Not yet recruiting |
NCT03266328 -
Procedure and In-hospital Outcome of Patients Under 40 Years Old Undergoing Primary Percutaneous Coronary Intervention for Acute ST Elevated Myocardial Infarction in Assiut University
|
N/A | |
Enrolling by invitation |
NCT04970238 -
Effect of Levosimendan on Left Ventricular Systolic Function and Heart Failure After PCI in Patients With Acute Anterior Myocardial Infarction
|
Phase 4 | |
Recruiting |
NCT02557217 -
NP202 for Treatment of Post -STEMI Left Ventricular Systolic Dysfunction
|
Phase 2 | |
Recruiting |
NCT02224534 -
Ticagrelor Versus Clopidogrel in Left Ventricular Remodeling After ST-segment Elevation Myocardial Infarction
|
Phase 4 | |
Completed |
NCT01136187 -
Trial Comparing Radial and Femoral Approach in Primary Percutaneous Coronary Intervention (PCI)
|
N/A | |
Not yet recruiting |
NCT04068116 -
Impact of Ischemic Post-conditioning
|
N/A | |
Not yet recruiting |
NCT04063345 -
Long-term Clinical Outcomes of intraVascular Ultrasound-guided vs Angiography-guided Primary pErcutaneous Intervention in Patients With Acute ST Segment Elevated Myocardial Infarction
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT03646357 -
BEtablocker Treatment After Acute Myocardial Infarction in Patients Without Reduced Left Ventricular Systolic Function
|
Phase 4 | |
Completed |
NCT03740776 -
The Eosinophils Percentage Predicts In-hospital Major Adverse Cardiac Events in STEMI Patients After PCI
|
||
Completed |
NCT03984071 -
The Predictive Value of eGFR for Adverse Cardiovascular Events in Patients With STEMI
|